🎉 M&A multiples are live!
Check it out!

Century Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Century Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Century Therapeutics Overview

About Century Therapeutics

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.


Founded

2018

HQ

United States of America
Employees

150

Website

centurytx.com

Financials

LTM Revenue $15.7M

LTM EBITDA n/a

EV

-$92.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Century Therapeutics Financials

Century Therapeutics has a last 12-month revenue of $15.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Century Therapeutics achieved revenue of $6.6M and an EBITDA of -$111M.

Century Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Century Therapeutics valuation multiples based on analyst estimates

Century Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.2M $6.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$121M -$111M XXX XXX XXX
EBITDA Margin -5423% -1692% XXX XXX XXX
Net Profit -$131M -$137M XXX XXX XXX
Net Margin -5858% -2074% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Century Therapeutics Stock Performance

As of April 15, 2025, Century Therapeutics's stock price is $0.

Century Therapeutics has current market cap of $43.0M, and EV of -$92.5M.

See Century Therapeutics trading valuation data

Century Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$92.5M $43.0M XXX XXX XXX XXX $-1.48

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Century Therapeutics Valuation Multiples

As of April 15, 2025, Century Therapeutics has market cap of $43.0M and EV of -$92.5M.

Century Therapeutics's trades at -5.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Century Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Century Therapeutics and 10K+ public comps

Century Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$92.5M XXX XXX XXX
EV/Revenue -14.0x XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -0.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Century Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Century Therapeutics Valuation Multiples

Century Therapeutics's NTM/LTM revenue growth is 84%

Century Therapeutics's revenue per employee for the last fiscal year averaged $44K, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Century Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Century Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Century Therapeutics and other 10K+ public comps

Century Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 195% XXX XXX XXX XXX
EBITDA Margin -1692% XXX XXX XXX XXX
EBITDA Growth -8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1608% XXX XXX XXX XXX
Revenue per Employee $44K XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 503% XXX XXX XXX XXX
R&D Expenses to Revenue 1628% XXX XXX XXX XXX
Opex to Revenue 2131% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Century Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Century Therapeutics M&A and Investment Activity

Century Therapeutics acquired  XXX companies to date.

Last acquisition by Century Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Century Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Century Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Century Therapeutics

When was Century Therapeutics founded? Century Therapeutics was founded in 2018.
Where is Century Therapeutics headquartered? Century Therapeutics is headquartered in United States of America.
How many employees does Century Therapeutics have? As of today, Century Therapeutics has 150 employees.
Who is the CEO of Century Therapeutics? Century Therapeutics's CEO is Mr. Brent Pfeiffenberger, M.B.A.,PhD.
Is Century Therapeutics publicy listed? Yes, Century Therapeutics is a public company listed on NAS.
What is the stock symbol of Century Therapeutics? Century Therapeutics trades under IPSC ticker.
When did Century Therapeutics go public? Century Therapeutics went public in 2021.
Who are competitors of Century Therapeutics? Similar companies to Century Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Century Therapeutics? Century Therapeutics's current market cap is $43.0M
What is the current revenue of Century Therapeutics? Century Therapeutics's last 12-month revenue is $15.7M.
What is the current EV/Revenue multiple of Century Therapeutics? Current revenue multiple of Century Therapeutics is -5.9x.
What is the current revenue growth of Century Therapeutics? Century Therapeutics revenue growth between 2023 and 2024 was 195%.
Is Century Therapeutics profitable? Yes, Century Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.